Getting Senolytics to the Right Cells: How Nanoparticles, Antibody Conjugates and CAR T Cells Are Engineered to Target Senescence

Drug delivery is the quiet bottleneck in longevity research. Researchers can identify senolytic and senomorphic compounds that act on senescent cells, but getting those compounds to reach senescent cells, and only those cells, is what determines whether the approach is therapeutically useful. Three delivery strategies now dominate the field: nanoparticles engineered to transport drugs directly to senescent or damaged tissues, antibody-drug conjugates that recognize membrane markers of senescence, and engineered immune cells that seek out and eliminate their targets. Each achieves specificity through a fundamentally different principle.

The Challenge of Senescent Cells: Why Targeted Delivery Matters

Senescent cells irreversibly stop proliferating, and this arrest serves as a protective mechanism preventing damaged cells from propagating. But the progressive accumulation of senescent cells over time is associated with loss of tissue homeostasis, contributing to the functional impairment of organs typically seen in ageing, according to researchers studying senescence mechanisms. The problem is therefore one of accumulation.

The delivery challenge follows directly. Researchers led by Salvador Macip's group, writing in Scientific Reports, put it bluntly: the senolytics tested so far lack specificity and carry significant off-target effects, which is why a targeted approach could be more clinically relevant. Off-target toxicity is not a peripheral concern. It is the central obstacle that justifies engineering an entire delivery apparatus around compounds that might otherwise work.

Nanoparticle-Based Systems: Precision at the Nanoscale

Nanoparticles are engineered to transport drugs, genes or other therapeutic molecules directly to senescent cells or damaged tissues, enhancing treatment efficacy and minimizing side effects. The nanoscale engineering compensates for shortcomings of traditional drugs, such as low stability and short half-life, maximizing bioavailability while minimizing the toxicity of delivery, according to a review of nanotherapy advances for senescence targeting.

The same review notes that nanomaterials' unique optical, magnetic and electrical properties underpin systems that can control drug release at the site where it is needed. Exosomes, described as natural nanoparticles of signaling molecules, represent one variant with potential for drug delivery and disease therapy. The unifying principle across these systems is that the carrier, not the drug, determines where the payload concentrates.

Antibody-Drug Conjugates: Guided Missiles for Senescent Cells

Antibody-drug conjugates combine the specificity of an antibody with the potency of a cytotoxic payload. The key is identifying a suitable target on the cell surface. Poblocka and colleagues proposed using an extracellular epitope of B2M, a membrane marker of senescence, as the target for specific delivery of toxic drugs into senescent cells.

Their proof of mechanism was direct. An ADC against B2M cleared senescent cells by releasing duocarmycin into them, while an isotype control ADC was not toxic to those cells. The effect depended on p53 expression, making it more evident in stress-induced senescence. This last detail matters: even a targeted conjugate's activity can depend on the biology of the senescent cell itself, not just on antibody binding.

Cell-Based Therapies: Engineering Immune Cells for Senescent Cell Clearance

Chimeric antigen receptor T cells take a different route to specificity. Rather than delivering a drug to a senescent cell, they engineer the patient's own T cells to recognize and eliminate target cells directly. CAR T cells are engineered to express a receptor that recognizes uPAR, an antigen highly expressed on the surface of senescent cells, enabling selective identification and destruction of those cells.

Memorial Sloan Kettering Cancer Center researchers, reporting on CAR T work against age-related diseases in mice, highlighted a practical distinction: cellular therapy can be engineered with safety features to mitigate side effects, and can simultaneously target multiple surface molecules, reducing the chance of attacking healthy cells. A single infusion may also offer long-lasting protection, in contrast to treatments required multiple times per day.

Comparing Advanced Delivery Systems for Senescent Cell Targeting

The three strategies achieve specificity through distinct mechanisms, and the differences determine which is suited to which therapeutic goal. Nanoparticles physically carry a payload; conjugates chemically link one; CAR T cells replace the payload with the immune cell itself. Use the table below to distinguish the classes and their underlying design principles.

Advanced delivery systems for targeting senescent cells
Delivery system type	Targeting mechanism principle	Key advantage
Nanoparticle-based systems (including exosomes)	Nanoscale carriers are engineered to transport drugs, genes or therapeutic molecules directly to senescent cells or damaged tissues, controlling drug release at the site	Enhanced bioavailability and treatment efficacy with minimized side effects and toxicity; compensates for low drug stability and short half-life
Antibody-drug conjugates (ADCs)	An antibody component binds a membrane marker overexpressed on senescent cells, such as the extracellular epitope of B2M, releasing the conjugated payload into the cell	Highly specific delivery of potent drugs to senescent cells, minimizing off-target effects; an isotype control ADC showed no toxicity
Cell-based therapies (CAR T cells)	Engineered T cells express a chimeric antigen receptor recognizing uPAR, an antigen highly expressed on senescent cell surfaces, enabling selective elimination	A single infusion may act long-lastingly; can be engineered with safety features and to target multiple surface molecules simultaneously, reducing attacks on healthy cells

One caveat follows from the evidence: these approaches target senescent cells by design, but demonstrated results vary. The ADC result was shown in a specific p53-dependent context, the CAR T findings were in mice, and the nanoparticle literature is largely conceptual and preclinical. None of these systems yet has established clinical trial efficacy data for senescence targeting, which this article does not attempt to report.

The Future of Targeted Senescent Cell Therapies

Researchers and developers should continue to prioritize the development and refinement of targeted delivery systems for senescent cells, focusing on enhancing specificity and minimizing off-target effects to unlock their full therapeutic potential. The convergence of the three approaches suggests the field is maturing beyond untargeted senolytics toward engineered precision.

The measurable indicator of progress is the publication of preclinical or early clinical trial results demonstrating significantly improved specificity for senescent cells and reduced systemic toxicity compared to untargeted approaches. The B2M conjugate and uPAR-directed CAR T work each provide a template; the next milestone is showing that such specificity holds up in human studies.